BackBioline Rx Overview

Bioline Rx Intangible Assets

Bioline Rx's intangible assets is $16M.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$16.35M
↑ 56.73% YoYΔ $5.92M vs prior year quarter

Peer average

Loading

Bioline Rx Intangible Assets History

Loading

Bioline Rx vs. peers: Intangible Assets Comparison

Loading

Bioline Rx Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Bioline Rx (BLRX) FAQ

As of the most recent data (March 2026), BLRX shows a intangible assets of $16M. That compares with $10M in the prior-year period — up 56.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BLRX's intangible assets is now $16M (was $10M) — a 56.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Bioline Rx is outperforming or lagging.

Tracking BLRX's intangible assets over time shows whether Bioline Rx is scaling, shrinking, or reshaping that part of the business. The current reading is $16M That compares with $10M in the prior-year period — up 56.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this intangible assets page, Stockcircle has Bioline Rx's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect intangible assets (currently $16M) with ownership activity and broader fundamentals.

Bioline Rx's intangible assets is $16M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.